IGKV1D-22 and neoplasm: Treatment with CCL2 blocking antibodies resulted in reduced S100A8/A9 expression and a significantly decreased number of pro-inflammatory monocytes in both spleen and lungs of 4T1.2-tumor bearing mice (Fig 3b-d).